| Oct 9 |
SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA
|
| Oct 9 |
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
|
| Oct 9 |
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
|
| Oct 8 |
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
|
| Oct 8 |
Startup led by John Maraganore raises $135M to build ‘future of RNAi’
|
| Oct 7 |
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
|
| Oct 7 |
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
|
| Oct 6 |
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
|
| Oct 3 |
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To Breakeven In The Near Future
|
| Oct 2 |
Here's Why You Should Add ALNY Stock to Your Portfolio Right Now
|
